Thursday May 25th 2017

Archive for November, 2011

Ottawa moving too slow on patient trials for MS treatment, patient believes

Ottawa moving too slow on patient trials for MS treatment, patient believes

Early phase patient trials for the experimental Liberation process are a waste of time, a multiple sclerosis patient says. “As far as I know, Phase 1 and Phase 2 doesn’t include the actual procedure,” said Yvonne Anderson of the Onslow area, who travelled [Read More]

‘Liberation’ clinical trial moving ahead

‘Liberation’ clinical trial moving ahead

The federal government has announced the next step in its plan to test the so-called “liberation” treatment for multiple sclerosis, while the provincial health minister said Saskatchewan is willing to participate in that project as well as forge ahead with its [Read More]

Ottawa seeks research proposals to study MS treatment

Ottawa seeks research proposals to study MS treatment

The federal government announced Friday it is ready to accept proposals from researchers who want to study an experimental treatment for people with multiple sclerosis. Health Minister Leona Aglukkaq announced the call for proposals to study the so-called liberation therapy [Read More]

 Page 1 of 3  1  2  3 »

Latest Topics

MS Study Alert: Share Your Thoughts About MS Research

MS Study Alert: Share Your Thoughts About MS Research

/About-the-Society/News/MS-Study-Alert-Share-Your-Thoughts-About-MS-Resea [Read More]

Mallinckrodt begins enrolment in Phase IV trial of HP Acthar gel for RRMS

Mallinckrodt begins enrolment in Phase IV trial of HP Acthar gel for RRMS

UK-based specialist pharmaceutical firm Mallinckrodt has begun patient enrolment in the Phase IV OPTIONS clinical trial [Read More]

First Results Announced from Second Phase III Trial of Oral Ozanimod in People with Relapsing MS

First Results Announced from Second Phase III Trial of Oral Ozanimod in People with Relapsing MS

/About-the-Society/News/First-Results-Announced-from-Second-Phase-III-Tria [Read More]

Experimental treatment tempers HLH, MS symptoms in mouse models, study shows

Experimental treatment tempers HLH, MS symptoms in mouse models, study shows

Immune diseases like multiple sclerosis and hemophagocytic lymphohistiocytosis unleash destructive waves of [Read More]

Celgene ’s Phase III trial of ozanimod for RMS meets primary endpoint

Celgene ’s Phase III trial of ozanimod for RMS meets primary endpoint

US-based biopharmaceutical firm Celgene has reported positive results from the Phase III RADIANCE clinical trial of [Read More]